Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions View by Topic View by Date Must Reads by Date Must reads for theWeek ending March 1, 2020 Death from unintentional injury is higher in cancer patients, Pembrolizumab plus chemoradiotherapy shows early promise in NSCLC, Abbreviated MRI bests digital breast tomosynthesis in finding cancer in dense breasts, Rare case of nasal cavity mantle cell lymphoma reported, Viral encephalitis associated with 2 cases of rituximab maintenance therapy, More must reads Must reads for theWeek ending February 23, 2020 Apalutamide benefit sustained in mCSPC regardless of next therapy, Seminoma: Risk-adapted strategy could mean less toxic chemo, Tumor neoantigenicity metric improves prediction of response to immunotherapy, Variants in common genes linked to endometrial cancer risk , Late effects in young cancer survivors underscore importance of high-risk screening, More must readsMust reads for theWeek ending February 9, 2020 Abbreviated MRI equals standard protocol for high-risk breast cancer screens, Glioma trials should track living well, not just longer, Colorectal cancer risk elevated in anticoagulated AF patients with lower GI bleeding, Survival for older AML patients better with HSCT from unrelated donors, Flow-mediated dilation of brachial artery predicts renal dysfunction in sickle cell disease, More must readsMust reads for theWeek ending February 2, 2020 Deferiprone noninferior to deferoxamine for iron overload in SCD, rare anemias, Novel mutations contribute to progression of venetoclax-treated CLL, Medical scribe use linked to lower physician burnout, ECHELON-1 update: A+AVD bests ABVD in Hodgkin lymphoma, Lenvatinib/pembrolizumab has good activity in advanced RCC, other solid tumors, More must readsMust reads for theWeek ending February 2, 2020 Deferiprone noninferior to deferoxamine for iron overload in SCD, rare anemias, Novel mutations contribute to progression of venetoclax-treated CLL, Medical scribe use linked to lower physician burnout, ECHELON-1 update: A+AVD bests ABVD in Hodgkin lymphoma, Lenvatinib/pembrolizumab has good activity in advanced RCC, other solid tumors, More must readsPages« first 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 last »